Luc Friboulet
Overview
Explore the profile of Luc Friboulet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
4205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parisi C, Benitez J, Lecourt H, DallOlio F, Aldea M, Blanc-Durand F, et al.
J Liq Biopsy
. 2025 Mar;
6:100164.
PMID: 40027306
Importance: Deregulation of anaplastic lymphoma kinase (ALK) occurs in 3-7% of advanced NSCLC mainly because of chromosomic rearrangements at the ALK locus. Next to its oncogenic function, ALK chimeric oncoprotein...
2.
Marinello A, Parisi C, Vasseur D, Combarel D, Bihoreau J, Lavaud P, et al.
JTO Clin Res Rep
. 2025 Feb;
6(3):100773.
PMID: 39990136
In this case report, we describe a case of sequential acquired fusion and V600E mutation observed in a patient with -mutated NSCLC treated with osimertinib and with combined selpercatinib and...
3.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, et al.
Nat Commun
. 2024 Oct;
15(1):9370.
PMID: 39478018
No abstract available.
4.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, et al.
Nat Commun
. 2024 Oct;
15(1):8603.
PMID: 39366934
Metastatic urothelial carcinoma (mUC) is a lethal cancer, with limited therapeutic options. Large-scale studies in early settings provided critical insights into the genomic and transcriptomic characteristics of non-metastatic UC. The...
5.
Vasseur D, Bigot L, Beshiri K, Florez-Arango J, Facchinetti F, Hollebecque A, et al.
Mol Cancer
. 2024 Oct;
23(1):221.
PMID: 39363320
Background: Understanding the resistance mechanisms of tumor is crucial for advancing cancer therapies. The prospective MATCH-R trial (NCT02517892), led by Gustave Roussy, aimed to characterize resistance mechanisms to cancer treatments...
6.
Lin J, Horan J, Tangpeerachaikul A, Swalduz A, Valdivia A, Johnson M, et al.
Cancer Discov
. 2024 Sep;
14(12):2367-2386.
PMID: 39269178
Three generations of tyrosine kinase inhibitors (TKI) have been approved for anaplastic lymphoma kinase (ALK) fusion-positive non-small cell lung cancer. However, none address the combined need for broad resistance coverage,...
7.
Facchinetti F, Loriot Y, Braye F, Vasseur D, Bahleda R, Bigot L, et al.
Clin Cancer Res
. 2024 Sep;
30(21):4943-4956.
PMID: 39226398
Purpose: Understanding resistance to selective FGFR inhibitors is crucial to improve the clinical outcomes of patients with FGFR2-driven malignancies. Experimental Design: We analyzed sequential ctDNA, ± whole-exome sequencing, or targeted...
8.
Grazini U, Markovets A, Ireland L, ONeill D, Phillips B, Xu M, et al.
Clin Cancer Res
. 2024 Apr;
30(18):4143-4154.
PMID: 38630555
Purpose: Osimertinib is an EGFR tyrosine kinase inhibitor indicated for the treatment of EGFR-mutated (EGFRm)-driven lung adenocarcinomas. Osimertinib significantly improves progression-free survival in first-line-treated patients with EGFRm advanced non-small cell...
9.
Bigot L, Sabio J, Poiraudeau L, Annereau M, Menssouri N, Helissey C, et al.
Eur Urol Oncol
. 2024 Mar;
7(3):527-536.
PMID: 38433714
Background: Genomic studies have identified new subsets of aggressive prostate cancer (PCa) with poor prognosis (eg, neuroendocrine prostate cancer [NEPC], PCa with DNA damage response [DDR] alterations, or PCa resistant...
10.
Vasseur D, Arbab A, Giudici F, Marzac C, Michiels S, Tagliamento M, et al.
NPJ Precis Oncol
. 2024 Feb;
8(1):51.
PMID: 38409229
Next-generation sequencing (NGS) assays based on plasma cell-free DNA (cfDNA) are increasingly used for clinical trials inclusion. Their optimized limit of detection applied to a large number of genes leads...